Health

#SFHS2608374VNotice Regarding Pharmaceutical Specialty Prices

🇫🇷France··Other·Medium Impact·View source ↗

AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.

🇬🇧 English

This notice sets the prices for specific pharmaceutical products, specifically the injectable solutions YESINTEK 45 mg and 90 mg by Biocon Biologics France. Businesses in France need to adjust their pricing and stock strategies accordingly as the new rates take effect shortly after official publication.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.

Key Changes

  • Sets new prices for YESINTEK 45 mg and 90 mg injectable solutions.
  • Prices effective shortly after official publication.
  • Impacts pharmaceutical pricing strategies in France.

Obligations

What this law requires

high

Update pricing for YESINTEK 45 mg (CIP 34009 303 335 1 8) to PFHT €1,020.04 and PPTTC €1,128.53

Pharmaceutical distributors and healthcare providers selling YESINTEK 45 mg in France
operational
high

Update pricing for YESINTEK 90 mg (CIP 34009 303 335 2 5) to PFHT €1,020.04 and PPTTC €1,128.53

Pharmaceutical distributors and healthcare providers selling YESINTEK 90 mg in France
operational
high

Implement the new prices effective from the fourth day following publication in the Journal officiel de la République française

Pharmaceutical distributors, pharmacies, and healthcare facilities distributing YESINTEK products in France
operational
medium

Adjust inventory and stock strategies to reflect the newly established pharmaceutical specialty prices

Pharmaceutical distributors and pharmacy managers handling YESINTEK inventory in France
operational

Affected Parties

Pharmaceutical companiesHealthcare providers

Tags

pharmaceuticals,pricing,healthcare